Skip to main content
Top
Published in: BMC Health Services Research 1/2015

Open Access 01-12-2015 | Research article

Cost of illness of the Cervical Cancer of the uterus in Japan - a time trend and future projections

Authors: Eijiro Hayata, Kanako Seto, Kayoko Haga, Takefumi Kitazawa, Kunichika Matsumoto, Mineto Morita, Tomonori Hasegawa

Published in: BMC Health Services Research | Issue 1/2015

Login to get access

Abstract

Background

Cervical cancer is associated with high morbidity and mortality rates among young women in Japan. The objective of this study was to assess and project the economic burden associated with cervical cancer in Japan and identify factors affecting future changes in this burden on society.

Methods

Utilizing government-based statistical nationwide data, we used the cost of illness (COI) method to estimate the COIs for 1996, 1999, 2002, 2005, 2008, and 2011 to make predictions for 2014, 2017, and 2020. The COI comprised direct and indirect costs (morbidity and mortality costs).

Results

The COI was estimated to have increased by 66% from 96.1 billion yen in 1996 to 159.9 billion yen in 2011. The number of deaths increased, but the proportion of those aged ≥65 years as a percentage of all deaths remained mostly unchanged, with no increase in the average age at death. The mortality cost per person was estimated to have increased (31.5 million yen in 1996 vs. 43.5 million yen in 2011). Assuming that the current trend in health-related indicators continues, the COI is predicted to temporarily decrease in 2014, followed by almost no change in 2020 (the estimated COI is 145.3–164.6 billion yen). The mortality cost per person is predicted to remain almost unchanged (39.4–46.3 million yen in 2020).

Conclusions

The fact that the life expectancy of affected individuals is not being prolonged and that the mortality in young individuals with a high human capital value is not decreasing may contribute to future sustainment of the COI. We believe that the results of the present study are applicable to discussions of disease control priorities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Center for Cancer Control and Information Services, National Cancer Center: Cancer Information Service Homepage. [http://ganjoho.jp/pro/statistics/gdb_year.html] Center for Cancer Control and Information Services, National Cancer Center: Cancer Information Service Homepage. [http://​ganjoho.​jp/​pro/​statistics/​gdb_​year.​html]
2.
go back to reference Uemura K, Kougo M, Okubo K, Okai T, Yoneyama K, Kiuchi Y. Cost-effectiveness analysis of initial treatment for cervical cancer patients. Clin Gynecol Obstet. 2008;62(2):209–16. Uemura K, Kougo M, Okubo K, Okai T, Yoneyama K, Kiuchi Y. Cost-effectiveness analysis of initial treatment for cervical cancer patients. Clin Gynecol Obstet. 2008;62(2):209–16.
3.
go back to reference Konno R, Sasagawa T, Fukuda T, Georges VK, Nadia D. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Obstet Gynecolog Ther. 2008;97(5):530–42. Konno R, Sasagawa T, Fukuda T, Georges VK, Nadia D. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Obstet Gynecolog Ther. 2008;97(5):530–42.
4.
go back to reference Arakawa I, Kawabayashi Y, Furuno M, Uchida M, Kawana T. Economic evaluation for the prevention of cervical cancer by vaccination—from the perspective of health insurance society and industry. Jpn J Cancer Chemother. 2013;40(4):493–8. Arakawa I, Kawabayashi Y, Furuno M, Uchida M, Kawana T. Economic evaluation for the prevention of cervical cancer by vaccination—from the perspective of health insurance society and industry. Jpn J Cancer Chemother. 2013;40(4):493–8.
8.
go back to reference Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985;7:61–80.PubMedPubMedCentral Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985;7:61–80.PubMedPubMedCentral
11.
go back to reference Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77:51–63.CrossRefPubMed Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77:51–63.CrossRefPubMed
12.
go back to reference Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60:429–62.CrossRefPubMed Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60:429–62.CrossRefPubMed
23.
go back to reference Haga K, Matsumoto K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of the stomach cancer in Japan—a time trend and future projections. BMC Health Serv Res. 2013;13:283.CrossRefPubMedPubMedCentral Haga K, Matsumoto K, Kitazawa T, Seto K, Fujita S, Hasegawa T. Cost of illness of the stomach cancer in Japan—a time trend and future projections. BMC Health Serv Res. 2013;13:283.CrossRefPubMedPubMedCentral
24.
go back to reference Ricciardi A, Larrgeon N, Giorgi Rossi P, Raffaele M, Chet C, Federici A, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori. 2009;95:146–52.PubMed Ricciardi A, Larrgeon N, Giorgi Rossi P, Raffaele M, Chet C, Federici A, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori. 2009;95:146–52.PubMed
25.
go back to reference Olivia J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:309–13.CrossRef Olivia J, Lobo F, Lopez-Bastida J, Zozaya N, Romay R. Indirect costs of cervical and breast cancers in Spain. Eur J Health Econ. 2005;6:309–13.CrossRef
26.
go back to reference Fleurence RL, Dixon JM, Milanova TF, Beusterien KM. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol. 2003;196:206–12.CrossRef Fleurence RL, Dixon JM, Milanova TF, Beusterien KM. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol. 2003;196:206–12.CrossRef
27.
go back to reference Prasad SR, Hill R. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. J Ky Med Assoc. 2008;106:271–6.PubMed Prasad SR, Hill R. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. J Ky Med Assoc. 2008;106:271–6.PubMed
28.
go back to reference Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30:6016–9.CrossRefPubMed Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30:6016–9.CrossRefPubMed
Metadata
Title
Cost of illness of the Cervical Cancer of the uterus in Japan - a time trend and future projections
Authors
Eijiro Hayata
Kanako Seto
Kayoko Haga
Takefumi Kitazawa
Kunichika Matsumoto
Mineto Morita
Tomonori Hasegawa
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2015
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-015-0776-5

Other articles of this Issue 1/2015

BMC Health Services Research 1/2015 Go to the issue